Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Good momentum in commercial CDMO business
CMOs showed an increasing reluctance to take on debt in 2022
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Approval to dramatically change CAR-T therapies landscape
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Subscribe To Our Newsletter & Stay Updated
